Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Prior treatment

• Subjects acceptable for allogeneic hematopoietic stem cell transplantation and have an available fully matched related donor.
• Treated with erythropoietin prior 3 months.
• Subjects who are receiving treatment from another clinical study, or have received another gene therapy.

Other illness

• Active bacterial, viral, or fungal infection.
• Subjects with severe psychiatric disorders to be unable to cooperate.
• History of complex autoimmune disease.
• Subjects with severe heart, lung and kidney diseases.
• Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or Investigator.

Lab values

• Persistent aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin value >3 X the upper limit of normal (ULN).
• With serious iron overload, serum ferritin>5000mg/ml.

Other

• Immediate family member with any known hematological tumor.
• Recently diagnosed as malaria.
• Subjects or guardians had resisted the guidance of the attending doctor.
• Subjects whom the investigators do not consider appropriate for participating in this clinical study

• Fully understand and voluntarily sign informed consent. 3-35years old. At least one legal guardian and/or Subjects to sign informed consent.
• Clinically diagnosed as β-thalassemia major, phenotypes including β0β0, β+β+、β
  • +β0, βEβ0 genotype.
• Subjects with no affection with EBV, HIV, CMV, TP, HAV, HBV and HCV.
• Subjects body condition eligible for autologous stem cell transplant.